1027 / 1601
ESTRO IG and Adaptive
Course Parikh Budapest 2018
SCRT + Chemo vs. CRT: Randomized Data
Polish, randomized phase III trial (2008-2014)
515 patients with fixed cT3 or cT4
Two Arms:
•
SCRT (5
×
5 Gy) and 3 cycles of FOLFOX4 with delayed surgery
•
CRT with 5-FU, LV, and oxaliplatin
Adjuvant chemotherapy not mandated, 39% received in both
Primary endpoint: R0 resection rate
Similar compliance and tolerability for each arm
R0 resection rates 77% vs. 71% (NS) and pCR 16% versus 12% (NS)
Lower acute toxicity with SCRT, similar post-op and late complications